BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 231 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q2 2020. The put-call ratio across all filers is 0.22 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $13,478,000 | -34.1% | 92,498 | -46.4% | 0.17% | -24.2% |
| Q1 2022 | $20,453,000 | -30.2% | 172,498 | -18.8% | 0.22% | -19.2% |
| Q4 2021 | $29,284,000 | -9.3% | 212,498 | -8.6% | 0.28% | -16.6% |
| Q3 2021 | $32,296,000 | +34.4% | 232,498 | -6.1% | 0.33% | +33.5% |
| Q2 2021 | $24,027,000 | +42.0% | 247,498 | 0.0% | 0.25% | +49.4% |
| Q1 2021 | $16,916,000 | +5.3% | 247,498 | +32.0% | 0.17% | +3.1% |
| Q4 2020 | $16,070,000 | -1.8% | 187,498 | -25.5% | 0.16% | -12.5% |
| Q3 2020 | $16,366,000 | +11.0% | 251,751 | +24.8% | 0.18% | +7.0% |
| Q2 2020 | $14,750,000 | +39.0% | 201,751 | -35.3% | 0.17% | +16.2% |
| Q1 2020 | $10,609,000 | -37.5% | 311,751 | 0.0% | 0.15% | -27.1% |
| Q4 2019 | $16,972,000 | +30.5% | 311,751 | 0.0% | 0.20% | +23.0% |
| Q3 2019 | $13,006,000 | -4.7% | 311,751 | 0.0% | 0.16% | -2.9% |
| Q2 2019 | $13,652,000 | -30.5% | 311,751 | -18.3% | 0.17% | -31.7% |
| Q1 2019 | $19,649,000 | +77.9% | 381,751 | +27.8% | 0.25% | +55.6% |
| Q4 2018 | $11,048,000 | – | 298,750 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knoll Capital Management, LLC | 450,422 | $6,251,857 | 14.11% |
| Liontrust Investment Partners LLP | 134,659 | $7,478,961 | 0.13% |
| Birchview Capital, LP | 7,365 | $102 | 0.07% |
| FNY Investment Advisers, LLC | 250 | $3 | 0.00% |
| FNY Investment Advisers, LLC | 18 | $0 | 0.00% |
| FNY Investment Advisers, LLC | 56 | $0 | 0.00% |
| McElhenny Sheffield Capital Management, LLC | 31 | $430 | 0.00% |
| Blue Trust, Inc. | 65 | $10 | 0.00% |
| IFP Advisors, Inc | 1 | $1 | 0.00% |